James Davis, PharmD, BCOP

💡 🧠 Hot off the press in its entirety... Our multi-center study looking into the safety of MMR vaccination in patients with myeloma receiving daratumumab maintenance after ASCT! Out now in @BloodPortfolio #BloodNeoplasia doi.org/10.1016/j.bneo…

a couple of our research projects (CMV reactivation and MMR with daratumumab) made John's #HOPA26 recap. check it out the @OncoPharmPod podcast here... open.spotify.com/episode/0l5fIo… @PharmDeetinib @kczmj @j_snyder0132 @VictoriaNachar @KG_PharmD @Warrick_PharmD

Efficacy of Stem Cell Boost (SCB) for CAR-T-related hematologic toxicity in #RRMM-RWE from the US multiple myeloma immunotherapy consortium rdcu.be/fa4XX Fortunate to have played a small part in this tremendous effort by #CindyVarga 👏🙌🎆 #MMSM #Medtwitter @BloodCancerJnl @thisisJamesD @khouri_jack @ForsbergMD @AimazAfrough @ldandersonjr @leshune @TomBmt133 #DorisHansen & many more

#Myeloma Paper of the Day: Analysis from US Multiple Myeloma Immunotherapy Consortium of real-world elranatamab data finds median PFS & OS 4.3 & 14.6 mos; elevated LDH & low Hgb predict poor outcomes; prior BCMA exposure reduced response depth: pubmed.ncbi.nlm.nih.gov/41896552/. #mmsm

Join Amir Ali, PharmD, BCOP, and James Davis, PharmD, BCOP (@ThisisJamesD) on 4/2 at 7 PM EDT for a #BispecificAntibodies in #Lymphoma #MedEd virtual event: bit.ly/NHLVirtual26-T

Measles is back. For myeloma patients after ASCT, MMR often gets delayed because of vaccine timing & concern about dara maintenance. This multicenter study provides reassuring safety data & should give clinicians confidence to vaccinate when appropriate. ashpublications.org/bloodneoplasia…

Great to see in @BloodPortfolio Neoplasia since it's a question our #MMsm patients ask all the time. "Can I get MMR 💉 on dara-len maintenance?" Short answer: 💯%, it seems! Long answer: Kudos to our PharmD colleagues within 🇺🇸 MM Consortium for leading the charge on this!

Pharmacist Leadership for #Lymphoma Care: Apply real-world case insights to support pharmacist decision-making with #BispecificAntibodies. Join Amir Ali, PharmD, BCOP, and James Davis, PharmD, BCOP (@ThisisJamesD), on 4/2 at 7 PM EDT for a virtual event: bit.ly/NHLVirtual26-T

Great article by @RahulBanerjeeMD @Bethfaiman et al reviewing the history and role of dexamethasone in plasma cell disorders. further solidifying the mantras #downwithdex and #DownWithDexExceptForCRS ascopubs.org/doi/10.1200/JC…

@DrGarethMorgan1 @Bethfaiman I saw the poster too and thought this Sankey diagram must have been a nightmare to create

This figure from my friend Peter Vorhees has to be the most complicated and weirdly beautiful I’ve ever seen

#ASH25 Come swing by our poster #4066. We show the incidence, risk factor and outcome of CV events during teclistamab in a multicenter registry! #USMMITC @MoffittNews @PennCardiology @PennCancer @md_addison @RahulBanerjeeMD @thisisJamesD amongst many others!

Earlier in the year we published efficacy of #pocketdex in patients receiving teclistamab, Sunday we present our group’s second pharmD led oral abstract at #ASH25 validating the safety of dex with talquetmab. Again, you don’t need toci for low grade CRS! doi.org/10.1182/blood-…

Getting excited to present our multi-center oral abstract at #ASH25 Saturday at 5:15pm investigating safety of MMR vaccines in patients on dara maintenance @kczmj @VictoriaNachar @KLratermann @AMDominickDO @KG_PharmD

#5 Stem cell boost as treatment for cytopenias after CART. Cindy Varga et al. @SurbhiSidanaMD @hhashmi87 @TomBmt133 Highly effective, safe, and practical. #ASH25 Link: meetings-api.hematology.org/api/abstract/v…

Myeloma / Plasma Cell Dyscrasia ~ #ASH25Top10 (or so) #mmsm #mmMRD #ASH25 - @mtmdphd – DRAFT Update: 12/1/25 v2 - cc @grpetersen1 – @IrenemGhobrial @Taxkourel @RahulBanerjeeMD @AuclairDan @JanakiramMurali @jmikhaelmd @End_myeloma @bdermanmd @szusmani @DrOlaLandgren

For patients with myeloma #MMsm and no response after 1 month of bispecific antibodies, should therapy be continued or changed? More by @RahulBanerjeeMD et al out now in @AjHematology. doi.org/10.1002/ajh.70… @AlGarfall

#Myeloma Paper of the Day: Real-world study of bispecific T-cell engager safety & efficacy in systemic AL #amyloidosis finds heme ORR 76% (66% CR, 7% VGPR), MRD-negative in 6/6 tested, cardiac & renal response in 64% & 100%; CRS in 45% (all G 1/2): pubmed.ncbi.nlm.nih.gov/41221958/. #mmsm

Dex for management of CRS assoc w/ talquetamab [GPRC5D-targeting bispecific antibody (bsAb)] in Pts w/ RRMM [Nov 3, 2025] McElwee et al. #ASH25 abs25-14627 PID 720 submit.hematology.org/program/presen… #mmsm #SuppOnc

10/ #ASH25 Abstract 720: 1st-line CRS Tx with dex in #MMsm bsAbs (McElwee @thisisJamesD et al) "Pocket dex": equal efficacy, way cheaper / simpler than toci, albeit >1 dose more likely. This makes outpt bsAb SUD *way* easier for pts. As I now say: #Downwithdex #ExceptforCRS !